Irinotecan plus oxaliplatin±G-CSF as second line therapy in patients with advanced 5-FU/leucovorin-refractory colorectal cancer (CC)

被引：0
|
作者：
Valencak, J
Lathan, B
Kornek, G
Raderer, M
Klein, G
Hejna, M
Brodovic, T
Weinländer, G
Depisch, D
Scheithauer, W
机构：
[1] Univ Vienna, Dept Int Med 1, Vienna, Austria
[2] Lathan Inst, Dortmund, Germany
[3] Wr Neustadt Gen Hosp, Neustadt, Germany
来源：
BRITISH JOURNAL OF CANCER | 1998年 / 78卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P47
引用
收藏
页码：36 / 36
页数：1
相关论文
共 50 条
  • [21] Oxaliplatin and high dose 24 hours 5-fluorouracile (5FU) plus leucovorin (LV) as second line chemotherapy in advanced colorectal cancer.
    Nobile, MT
    Gozza, A
    Heouaine, A
    Chiara, S
    Murolo, M
    Cosso, M
    Lionetto, R
    Rosso, R
    ANNALS OF ONCOLOGY, 2000, 11 : 77 - 77
  • [22] Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients
    Gil-Delgado, MA
    Bastian, G
    Guinet, FO
    Spano, JP
    Taillibert, S
    Rocher, MA
    Castaing, D
    Adam, R
    Urien, S
    Bismuth, H
    Khayat, D
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2004, 27 (03): : 294 - 298
  • [23] 5-FU/leucovorin (5FU/LV) combined with irinotecan (CPT-11) and oxaliplatin (FOLFIRINOX) as second-line chemotherapy in patients with metastatic pancreatic adenocarcinoma.
    Assaf, E.
    Verlinde-Carvalho, M.
    Delbaldo, C.
    Grenier, J.
    Sellam, Z.
    Pouessel, D.
    Sobhani, I.
    Tayar, C.
    Piedbois, P.
    Culine, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [24] A Randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig
    Goldstein, David
    Gorbounova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Granov, Dmitry A.
    Hossain, Anwar M.
    Blatter, Johannes
    Kaiser, Christopher
    Ma, Doreen
    ONCOLOGY, 2007, 73 (1-2) : 9 - 20
  • [25] A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer
    Underhill, Craig R.
    Goldstein, David
    Gorbunova, Vera A.
    Biakhov, Mikhail Y.
    Bazin, Igor S.
    Melemed, Allen
    Hossain, Anwar
    Granov, Dmitry A.
    ANNALS OF ONCOLOGY, 2006, 17 : 118 - 118
  • [26] Phase III study of 5-fluorouracil/leucovorin plus oxaliplatin versus capecitabine plus oxaliplatin as first line therapy in patients with advanced colorectal cancer (ACRC)
    Porschen, R
    Arkenau, T
    Kubicka, S
    Schmoll, HJ
    Seufferlein, T
    Graeven, U
    Grothey, A
    GASTROENTEROLOGY, 2005, 128 (04) : A438 - A438
  • [27] Randomized phase II study of combined infusional leucovorin sodium (LVNa) and 5-FU versus the sequential administration of leucovorin calcium (LVCa) followed by 5-FU with irinotecan or oxaliplatin in patients (pts) with metastatic colorectal cancer (mCRC)
    Bleiberg, H.
    Vandebroek, A.
    Deleu, I.
    Vergauwe, P.
    Kalantari, H. Rezael
    D'Haens, G.
    Paesmans, M.
    Peeters, M.
    Efira, A.
    Humblet, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Gunnar Folprecht
    Susanne Hamann
    Katharina Schütte
    Tanja Trarbach
    Jan Stoehlmacher-Williams
    Gerhard Ehninger
    BMC Cancer, 14
  • [29] Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancer
    Folprecht, Gunnar
    Hamann, Susanne
    Schuete, Katharina
    Trarbach, Tanja
    Stoehlmacher-Williams, Jan
    Ehninger, Gerhard
    BMC CANCER, 2014, 14
  • [30] Second-line treatment of advanced colorectal cancer with a biweekly oxaliplatin plus irinotecan combination regimen
    Schüll, B
    Kornek, GV
    Schmid, K
    Raderer, M
    Ulrich-Pur, H
    Fiebiger, W
    Schneeweiss, B
    Lenauer, A
    Depisch, D
    Scheithauer, W
    ONKOLOGIE, 2002, 25 (04): : 358 - 362
12345